Drugs / BMS-817399
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01404585 | Sep 2011 → Feb 2013 | rheumatoid arthritis | Bristol-Myers Squibb | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMS-817399 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01404585 ↗ |
| Action | Inhibit | “C-C chemokine receptor type 1 antagonist” CHEMBL3334824 ↗ |
| Modality | Small molecule | — CHEMBL3334824 ↗ |
| Route | Oral | “Tablets, Oral, 200 mg, twice daily, 12 weeks” NCT01404585 ↗ |
| Target | CCR1 | “C-C chemokine receptor type 1 antagonist” CHEMBL3334824 ↗ |